Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhib...
March 07 2019 - 5:30PM
Business Wire
Gilead Sciences, Inc. (NASDAQ:GILD) today announced findings
from two studies that support the further development of GS-6207, a
novel, selective, first-in-class inhibitor of HIV-1 capsid
function, for potential future use as part of long-acting HIV
combination therapy. Interim blinded data from a Phase 1 study in
healthy trial participants demonstrated that single doses of
GS-6207 of up to 450 mg, administered subcutaneously, achieved
sustained concentration levels and were well-tolerated. Separately,
in vitro data demonstrated picomolar potency with GS-6207,
including against HIV strains resistant to other antiretroviral
(ARV) classes. The data were presented at the 2019 Conference on
Retroviruses and Opportunistic Infections (CROI) in Seattle
(Session O-06).
“These studies indicate that GS-6207, a first-in-class,
investigational capsid inhibitor, may represent a novel approach to
HIV treatment due to its long-acting characteristics and potent
antiviral activity seen in vitro,” said John McHutchison, AO, MD,
Chief Scientific Officer and Head of Research and Development,
Gilead Sciences. “The data presented at CROI support advancing
GS-6207 to the next phase of clinical trials to gain a deeper
understanding of its potential role as a long-acting agent for
people living with HIV.”
GS-6207 was evaluated in 40 healthy trial participants in an
ongoing Phase 1 randomized, blinded, placebo-controlled, safety,
tolerability and PK study. The participants were randomized (4:1)
in four staggered single dose escalation cohorts to receive GS-6207
(n=8/cohort) or placebo (n=2/cohort), at 30, 100, 300 or 450 mg.
Through 20 weeks (30 mg cohort) to 4 weeks (450 mg cohort) of
study, there were no deaths, serious adverse events (AEs) or Grade
3 or 4 AEs. Most AEs were mild (Grade 1) and resolved. PK
parameters for the 30 mg and 100 mg cohorts have been estimated;
analyses for the 300 mg and 450 mg cohorts are ongoing. The PK
profile of subcutaneously administered GS-6207 is consistent with
sustained delivery, supporting a dosing interval of at least 3
months at doses greater than 100mg.
The in vitro study evaluated the pharmacological profile of
GS-6207 – which demonstrated up to >100-fold greater potency
than certain commonly prescribed ARVs and synergistic antiviral
activity when combined with the ARVs tenofovir alafenamide,
efavirenz, dolutegravir or darunavir. The in vitro study also
demonstrated that GS-6207 retains full potency against a broad
range of HIV-1 strains resistant to other ARV classes.
Gilead has initiated a Phase 1b study of GS-6207 in people
living with HIV.
GS-6207 is an investigational therapy and not approved by any
regulatory body globally; its safety and efficacy have not been
established. There is no cure for HIV or AIDS.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For nearly 30 years, Gilead has been a leading innovator in the
field of HIV, driving advances in treatment, prevention, testing
and linkage to care, and cure research. Today, it’s estimated that
more than 11.5 million people living with HIV globally receive
antiretroviral therapy provided by Gilead or one of the company’s
manufacturing partners.
For more information on Gilead Sciences, please visit the
company’s website at www.gilead.com.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors. In
addition, we may have difficulties conducting the Phase 1b clinical
study of GS-6207 as currently anticipated. In addition, we may
observe unfavorable results from additional studies GS-6207 and
Gilead may make a strategic decision to discontinue development of
GS-6207 if, for example, Gilead believes commercialization will be
difficult relative to other opportunities in its pipeline. As a
result, GS-6207 may never be successfully commercialized. These
risks, uncertainties and other factors could cause actual results
to differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Annual Report on Form 10-K for the year ended
December 31, 2018, as filed with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
Gilead and the Gilead logo are trademarks of
Gilead Sciences, Inc. or its related companies.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190307005645/en/
Sung Lee, Investors(650) 524-7792
Ryan McKeel, Media(650) 377-3548
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024